缺血性卒中治疗的疗效与安全性:伞状综述
结果显示tPA、依达拉奉联合tPA、tPA联合机械取栓、针灸联合西药、活血化瘀中药联合西药等可改善神经功能缺损与日常生活活动能力,且不良反应轻微。
要点
- tPA、依达拉奉联合tPA、tPA联合机械取栓、针灸联合西药、活血化瘀中药联合西药为改善神经功能与日常生活活动能力的最佳选择。
- 溶栓治疗、机械取栓、干细胞疗法、抗血小板药、他汀类等可改善神经功能缺损与日常生活活动能力,不良反应轻微。
- 川芎嗪、红花黄色素、他汀类、白蛋白、秋水仙碱、MLC601、丹酚酸类及丁苯酞显示严重不良事件、颅内出血或死亡风险。
核心结论
- tPA、依达拉奉联合tPA、tPA联合机械取栓、针灸联合西药、活血化瘀中药联合西药是改善缺血性卒中患者神经功能与日常生活活动能力的最佳药物选择。
主要发现
- 溶栓治疗(tPA;阿替普酶、替奈普酶和去氨普酶)、机械取栓、依达拉奉联合tPA、干细胞疗法、支架取栓器、针灸联合西药、自体骨髓基质细胞、抗血小板药(阿司匹林、氯吡格雷和替罗非班)、他汀类、活血化瘀中药联合西药(脑栓通胶囊、银杏叶、通窍活血汤、血塞通注射液)可改善神经功能缺损与日常生活活动能力,不良反应轻微。
- 川芎嗪、红花黄色素、他汀类、白蛋白、秋水仙碱、MLC601、丹酚酸类及DL-3-正丁基苯酞显示严重不良事件、颅内出血或死亡风险。
临床怎么用
- 对于缺血性卒中患者,可优先考虑tPA、依达拉奉联合tPA、tPA联合机械取栓、针灸联合西药、活血化瘀中药联合西药以改善神经功能与日常生活活动能力。
- 使用川芎嗪、红花黄色素、他汀类、白蛋白、秋水仙碱、MLC601、丹酚酸类或丁苯酞时需警惕严重不良事件、颅内出血或死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Ischemic stroke is a leading cause of morbidity and mortality in neurological diseases. Numerous studies have evaluated the efficacy and safety of ischemic stroke therapies, but clinical data were largely inconsistent. Therefore, it is necessary to summarize and analyze the published clinical research data in the field. Objective: We aimed to perform an umbrella review to evaluate the efficacy and safety of ischemic stroke therapies. Methods: We conducted a search for meta-analyses and systematic reviews on PubMed, the Cochrane Library, and the Web of Science to address this issue. We examined neurological function deficit and cognitive function scores, quality of life, and activities of daily living as efficacy endpoints and the incidence of adverse events as safety profiles. Results: Forty-three eligible studies including 377 studies were included in the umbrella review. The results showed that thrombolytic therapy (tPA; alteplase, tenecteplase, and desmoteplase), mechanical thrombectomy (MTE), edaravone with tPA, stem cell-based therapies, stent retrievers, acupuncture with Western medicines, autologous bone marrow stromal cells, antiplatelet agents (aspirin, clopidogrel, and tirofiban), statins, and Western medicines with blood-activating and stasis-dispelling herbs (NaoShuanTong capsule, Ginkgo biloba, Tongqiao Huoxue Decoction, Xuesaitong injection) can improve the neurological deficits and activities of daily living, and the adverse effects were mild for the treatment of ischemic stroke. Moreover, ligustrazine, safflower yellow, statins, albumin, colchicine, MLC601, salvianolic acids, and DL-3-n-butylphthalide showed serious adverse events, intracranial hemorrhage, or mortality in ischemic stroke patients. Conclusion: Our study demonstrated that tPA, edaravone and tPA, tPA and MTE, acupuncture and Western medicines, and blood-activating and stasis-dispelling herbs with Western medicines are the optimum neurological function and activities of daily living medication for patients with ischemic stroke. Systematic Review Registration: https://inplasy.com/, identifier [INPLASY202250145].
引用
- Li Y, Cui R, Fan F, et al. The Efficacy and Safety of Ischemic Stroke Therapies: An Umbrella Review. Front Pharmacol. 2022. PMID: 35935837. doi:10.3389/fphar.2022.924747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。